Comparative analysis of seven standardised commercially available grass extracts for sublingual immunotherapy in liquid formulation
Main Article Content
Keywords
allergen, Sublingual immunotherapy, grass pollen, allergenic extracts, clinical efficacy
Abstract
Sublingual immunotherapy with allergens requires high allergen doses to achieve the desired clinical efficacy. Given the current differences among products on the market, this study aims to compare seven therapeutic sublingual grass pollen extracts to quantify the Group 5 allergen concentrations, assess their biological activity and characterise allergenic profiles. The extracts were analysed by protein quantification (Bradford method), characterisation of the protein profile (SDS-PAGE) and determination of biological activity (ELISA inhibition and immunoblotting). Major allergens (Group 5) were also quantified using a sandwich ELISA. Differences were observed between the various allergenic extracts. Protein content ranged from 27 to 231 µg/mL, with Apioral Forte, SlitOne Ultra and Sublivac showing similar protein profiles. These extracts also displayed the highest biological activity, while the quantification of major Group 5 allergens was greatest in Apioral Forte, Sublivac and Tol Forte. The differences observed between extracts may have a relevant clinical impact. It is essential to have standardised, comparative analytical methods that allow specialists to select the most appropriate treatment.
References
2. Tosca MA, Licari A, Olcese R, Marseglia G, Sacco O, Ciprandi G. Immunotherapy and asthma in children. Front Pediatr. 2018;6:231. https://doi.org/10.3389/fped.2018.00231
3. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006 Feb;61(2):151–65. https:// doi.org/10.1111/j.1398-9995.2006.01002.x
4. Dramburg S, Hilger C, Santos AF, de las Vecillas L, Aalberse RC, Acevedo N, et al. EAACI Molecular Allergology User’s Guide 2.0. Pediatr Allergy Immunol. 2023;34(S28):e13854. https://doi.org/10.1111/pai.13854
5. Lei DK, Grammer LC. An overview of allergens. Allergy Asthma Proc. 2019;40(6):362–5. https://doi.org/10.2500/ aap.2019.40.4247
6. Zimmer J, Bridgewater J, Ferreira F, van Ree R, Rabin RL, Vieths S. The history, present and future of allergen standardization in the United States and Europe. Front Immunol. 2021;12:725831. https://doi.org/10.3389/fimmu.2021.725831
7. Ezhuthachan ID, Banks TA, Cerise JE, Wong SC, Ponda P. Allergen immunotherapy extract shortages and their effects on clinical care: A Work Group Report of the AAAAI Immunotherapy, Allergen Standardization, and Allergy Diagnostics Committee. J Allergy Clin Immunol Pract. 2022;10(2):444–52. https://doi.org/10.1016/j.jaip.2021.10.057
8. Frisk CA, Adams-Groom B, Smith M. Isolating the species element in grass pollen allergy: A review. Sci Total Environ. 2023;883:163661. https://doi.org/10.1016/j.scitotenv.2023. 163661
9. SEAIC. Guía Farmacoterapéutica de Inmunoterapia [Internet]. 2013 [cited 2025 May 5]. Available from: https://www.seaic. org/inicio/guia-farmacoterapeutica-de-inmunoterapia
10. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). ICH Q2(R2) guideline on validation of analytical procedures. EMA/CHMP/ ICH/82072/2006. The Netherlands: European Medicines Agency; 2023.
11. Alvarez-Perea A. Informe Alergológica 2015 [Internet]. 2017 [cited 2025 May 2]. Available from: http://www.seaic.org/ inicio/en-portada/alergologica-2015.html
12. Focke M, Marth K, Flicker S, Valenta R. Heterogeneity of commercial timothy grass pollen extracts. Clin Exp Allergy. 2008;38(8):1400–8. https://doi.org/10.1111/j.1365-2222.2008.03031.x
13. Sander I, Fleischer C, Meurer U, Brüning T, Raulf-Heimsoth M. Allergen content of grass pollen preparations for skin prick testing and sublingual immunotherapy. Allergy. 2009;64(10):1486–92. https://doi. org/10.1111/j.1398-9995.2009.02040.x
14. Mösges R, Pasch N, Schlierenkämper U, Lehmacher W. Comparison of the biological activity of the most common sublingual allergen solutions made by two European manufacturers. Int Arch Allergy Immunol. 2006;139(4):325–9. https://doi.org/10.1159/000091604
15. Schmidt H, Gelhaus C, Nebendahl M, Janssen O, Petersen A. Characterization of Phleum pratense pol-len extracts by 2-D DIGE and allergen immunoreactivity. Proteomics. 2010;10(24):4352–62. https://doi.org/10.1002/ pmic.201000451
16. Moreno Benítez F, Espinazo Romeu M, Letrán Camacho A, Mas S, García-Cózar FJ, Tabar AI. Variation in allergen content in sublingual allergen immunotherapy with house dust mites. Allergy. 2015;70(11):1413–20. https://doi.org/10.1111/ all.12694
17. European Medicines Agency. Committee for medicinal products for human use (CHMP). Guideline on allergen products: Production and quality issues. EMEA/CHMP/BWP/304831. London: European Medicines Agency; 2008.
18. Passalacqua G, Sastre J, Pfaar O, Wahn U, Demoly P. Comparison of allergenic extracts from different origins: The value of the FDA’s bioequivalent allergy unit (BAU). Expert Rev Clin Immunol. 2016;12(7):733–9. https://doi.org/10.1080/ 1744666X.2016.1187561
19. Van Ree R, Chapman MD, Ferreira F, Vieths S, Bryan D, Cromwell O, et al. EU Forum: The CREATE Project: Development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy. 2008;63(3):310–26. https://doi. org/10.1111/j.1398-9995.2007.01612.x